Adamas Pharmaceuticals, Inc. (ADMS) Reaches $38.65 High on Jan, 18; Evertec (EVTC) Shorts Increased By 7.9%

January 18, 2018 - By Stephen Andrade

The stock of Adamas Pharmaceuticals, Inc. (NASDAQ:ADMS) reached all time high today, Jan, 18 and still has $40.97 target or 6.00% above today’s $38.65 share price. This indicates more upside for the $880.41 million company. This technical setup was reported by Barchart.com. If the $40.97 PT is reached, the company will be worth $52.82M more. The stock increased 5.49% or $2.01 during the last trading session, reaching $38.65. About 258,585 shares traded. Adamas Pharmaceuticals, Inc. (NASDAQ:ADMS) has declined 0.40% since January 18, 2017 and is downtrending. It has underperformed by 17.10% the S&P500.

Evertec Incorporated (NYSE:EVTC) had an increase of 7.9% in short interest. EVTC’s SI was 1.22M shares in January as released by FINRA. Its up 7.9% from 1.13M shares previously. With 859,500 avg volume, 1 days are for Evertec Incorporated (NYSE:EVTC)’s short sellers to cover EVTC’s short positions. The stock decreased 0.71% or $0.1 during the last trading session, reaching $14.05. About 148,232 shares traded. EVERTEC, Inc. (NYSE:EVTC) has risen 21.35% since January 18, 2017 and is uptrending. It has outperformed by 4.65% the S&P500.

Analysts await Adamas Pharmaceuticals, Inc. (NASDAQ:ADMS) to report earnings on February, 27. They expect $-1.15 EPS, down 69.12% or $0.47 from last year’s $-0.68 per share. After $-1.04 actual EPS reported by Adamas Pharmaceuticals, Inc. for the previous quarter, Wall Street now forecasts 10.58% negative EPS growth.

Among 11 analysts covering Adamas Pharmaceuticals (NASDAQ:ADMS), 10 have Buy rating, 1 Sell and 0 Hold. Therefore 91% are positive. Adamas Pharmaceuticals had 26 analyst reports since August 7, 2015 according to SRatingsIntel. The firm has “Outperform” rating by Credit Suisse given on Thursday, December 24. Noble Financial maintained Adamas Pharmaceuticals, Inc. (NASDAQ:ADMS) on Wednesday, August 9 with “Buy” rating. Piper Jaffray maintained the shares of ADMS in report on Tuesday, August 8 with “Buy” rating. On Tuesday, August 15 the stock rating was maintained by Mizuho with “Buy”. The company was maintained on Friday, November 3 by Mizuho. The rating was downgraded by TheStreet on Friday, October 16 to “Sell”. The stock has “Buy” rating by Zacks on Friday, August 7. Mizuho maintained Adamas Pharmaceuticals, Inc. (NASDAQ:ADMS) rating on Thursday, May 12. Mizuho has “Neutral” rating and $16 target. As per Friday, September 15, the company rating was maintained by Needham. Mizuho maintained Adamas Pharmaceuticals, Inc. (NASDAQ:ADMS) on Tuesday, June 6 with “Buy” rating.

Adamas Pharmaceuticals, Inc., a pharmaceutical company, discovers, develops, and sells chrono-synchronous therapies for chronic neurologic disorders. The company has market cap of $880.41 million. The companyÂ’s product portfolio comprises ADS-5102, a chrono-synchronous amantadine therapy for the treatment of levodopa-induced dyskinesia in patients with ParkinsonÂ’s disease. It currently has negative earnings. The Company’s portfolio also comprises of Namzaric capsules; and Namenda XR (memantine hydrochloride) extended release capsules for the treatment of moderate to severe AlzheimerÂ’s disease.

Among 7 analysts covering Evertec (NYSE:EVTC), 1 have Buy rating, 2 Sell and 4 Hold. Therefore 14% are positive. Evertec had 21 analyst reports since August 14, 2015 according to SRatingsIntel. The stock of EVERTEC, Inc. (NYSE:EVTC) has “Outperform” rating given on Wednesday, September 30 by Cowen & Co. Compass Point initiated the shares of EVTC in report on Friday, April 15 with “Buy” rating. Goldman Sachs downgraded the shares of EVTC in report on Wednesday, January 17 to “Sell” rating. On Friday, July 29 the stock rating was maintained by Compass Point with “Buy”. The stock of EVERTEC, Inc. (NYSE:EVTC) has “Hold” rating given on Wednesday, November 8 by Deutsche Bank. The stock of EVERTEC, Inc. (NYSE:EVTC) earned “Buy” rating by Compass Point on Thursday, February 25. The stock of EVERTEC, Inc. (NYSE:EVTC) has “Hold” rating given on Tuesday, September 26 by Stifel Nicolaus. Stifel Nicolaus maintained the shares of EVTC in report on Wednesday, August 2 with “Hold” rating. The rating was downgraded by Deutsche Bank on Thursday, November 5 to “Hold”. On Wednesday, November 8 the stock rating was maintained by Stifel Nicolaus with “Buy”.

Receive News & Ratings Via Email - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings with our FREE daily email newsletter.

Free Email Newsletter

Enter your email address below to get the latest news and analysts' ratings for your stocks with our free daily email newsletter:


Recent Posts